Wednesday, December 17, 2025 11:54:37 AM
Looking at the numbers posted by rx7171, I have no reason to challenge what they’ve provided below.
Dizziness. 26.6%
Confusional state. 9.1%
Fall +1.8% improvement
Depressed mood. 2.6%
Headache. 3.7%
Anxiety. 0.8%
Balance disorder. 5.3%
Disorientation. 5.4%
My question is: Were all of these conditions directly attributable to Blarcamesine? Could there have been other situations that contributed to these supposed side effects?
Take for example dizziness and balance disorder. Depending on the age(s) of the participants, dizziness and balance disorder are common among the elderly. At age 80, I experience these on occasion when getting out of bed. The same applies to my younger brother (age 78) and my wife (age 77). My family doctor (early forties) complains of the same conditions. These are have been shown to be due to inner ear blockages which impact equilibrium. Were the complainants checked for conditions that might have accounted for these symptoms?
What about disorientation and confusional state? I know of a lady who had been taken to the emergency room twice in the past four months suffering from these very symptoms. She was found to have a bladder infection on both occasions. The doctors said in each case that urinary tract infections are often accompanied by disorientation and confusion. UTI’s are more common among the elderly. Were those suffering from these side effects checked for other conditions that might have contributed to these symptoms?
I may be out in left field here but am unsure that all of these symptoms were in all cases properly attributable to Blarcamesine.
Bill
Dizziness. 26.6%
Confusional state. 9.1%
Fall +1.8% improvement
Depressed mood. 2.6%
Headache. 3.7%
Anxiety. 0.8%
Balance disorder. 5.3%
Disorientation. 5.4%
My question is: Were all of these conditions directly attributable to Blarcamesine? Could there have been other situations that contributed to these supposed side effects?
Take for example dizziness and balance disorder. Depending on the age(s) of the participants, dizziness and balance disorder are common among the elderly. At age 80, I experience these on occasion when getting out of bed. The same applies to my younger brother (age 78) and my wife (age 77). My family doctor (early forties) complains of the same conditions. These are have been shown to be due to inner ear blockages which impact equilibrium. Were the complainants checked for conditions that might have accounted for these symptoms?
What about disorientation and confusional state? I know of a lady who had been taken to the emergency room twice in the past four months suffering from these very symptoms. She was found to have a bladder infection on both occasions. The doctors said in each case that urinary tract infections are often accompanied by disorientation and confusion. UTI’s are more common among the elderly. Were those suffering from these side effects checked for other conditions that might have contributed to these symptoms?
I may be out in left field here but am unsure that all of these symptoms were in all cases properly attributable to Blarcamesine.
Bill
Bullish
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
